Pfizer (PFE) has long been a strong dividend stock. The big pharma area is littered with companies that pay nice yields. But PFE has made its name with investors by paying a large, well-covered dividend for many years. Like other big pharmas, PFE always is on the prowl for its next acquisition. But to its credit, it has used excess cash consistently to return to shareholders by a billion each year. And with its newly-announced dividend increase, it is once again reaffirming its commitment to those who hold its stock. In this article, using data from Seeking Alpha and charts I’ve created, I’ll take a look at PFE’s new dividend obligation in light of its FCF production as well as the raised buyback authorization.
Pfizer Giving You A Raise
12/21/17
By Josh Arnold, SeekingAlpha
Stories you Need to Know
- David Nevins Interviews Dr. Matthew Frieman, Associate Professor, University of Maryland School of Medicine
- Immunic Reports Year End 2020 Financial Results
- Amneal Reports Fourth Quarter and Full Year 2020 Financial Results
- Relivant to Acquire Silicon Therapeutics for $450 Million
- Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
- Pacira BioSciences Reports Full-Year and Fourth Quarter 2020 Financial Results
- MTBC Reports Record Full Year 2020 Results
- Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update

